Hostname: page-component-77c89778f8-gvh9x Total loading time: 0 Render date: 2024-07-17T06:38:48.044Z Has data issue: false hasContentIssue false
  • English
  • Français

Clinical effects of central antagonist of cholecystokinin-1 receptors GB-115 in patients with Generalized Anxiety Disorder

Published online by Cambridge University Press:  01 September 2022

O. Dorofeeva ,
T. Syunyakov ,
M. Metlina  and
N. Ivashkina
O. Dorofeeva*
Affiliation:
FSBI “Zakusov Institute Of Pharmacology”, Department Of Pharmacological Genetics, Moscow, Russian Federation
T. Syunyakov
Affiliation:
FSBI “Zakusov Institute Of Pharmacology”, Department Of Pharmacological Genetics, Moscow, Russian Federation
M. Metlina
Affiliation:
FSBI “Zakusov Institute Of Pharmacology”, Department Of Pharmacological Genetics, Moscow, Russian Federation
N. Ivashkina
Affiliation:
FSBI “Zakusov Institute Of Pharmacology”, Department Of Pharmacological Genetics, Moscow, Russian Federation
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

The pilot clinical study of GB-115, a new peptide antagonist of central cholecystokinin-1 receptors, revealed that drug was clinically effective in patients with generalized anxiety disorder (GAD) at dose 6 mg daily. Here, we provide results of post-hoc analysis of changes of anxiety and fatigue symptoms to give characterization of its clinical effects in clinically relevant doses.

Objectives

To research the changes of anxiety- and fatigue-related symptoms during GB-115 treatment in patients with generalized anxiety disorder (GAD).

Methods

Patients with GAD without somatic diseases aged 18-55 years were eligible in the study. Patients were prescribed with GB-115 6 mg daily for 21 days. Anxiety and fatigue symptoms were assessed with Hamilton Anxiety Rating Scale (HARS) and Multidimensional Fatigue Inventory (MFI-20). Variables are described as medians and interquartile range (IQR). Pre-post comparisons were performed using the Friedman ANOVA at 2-side p-value <0.05.

Results

25 patients diagnosed with GAD (8 males, 17 females; median [IQR] age: 34 [29.75, 43.0]) included in the analysis. Median [IQR] HARS total score decreased from 22 [20, 24.5] to 19 [16, 20], 13 [10.5, 15.5], 9 [5.5, 11] and 5 [3.5, 8] on the Day 3,7,14 and 21, respectively (χ2=95.07, df=4, p<0.001). Median [IQR] MFI-20 score decreased from 70 [46, 75.5] to 59 [41, 74.5], 52 [37.5, 64.5], 37 [26.5, 63] and 28 [24, 48.5] on the Day 3, 7, 14 and 21, respectively (χ2= 55.41, df=4, p<0.001). None of patients had stimulation-related side effects.

Conclusions

GB-115 action in the treatment of GAD patients is characterized with anxiolytic action with mild psychostimulant properties.

Disclosure

No significant relationships.

Keywords

anxiety disordercholecystokininanxiolytic
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S388
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.